Hormone receptor (HR)‐positive and human epidermal growth factor receptor 2 (HER2)‐
negative breast cancer is defined by the presence of the estrogen receptor and/or the …

Background Aromatase inhibitors are associated with consistent improvements in disease-
free survival but not in overall survival. We conducted a literature-based meta-analysis of …

Background The administration of endocrine therapy for 5 years substantially reduces
recurrence rates during and after treatment in women with early-stage, estrogen-receptor …

Background For postmenopausal women with hormone-receptor–positive breast cancer, the
most effective duration for adjuvant therapy with an aromatase inhibitor remains unclear …

Purpose To update the ASCO clinical practice guideline on adjuvant endocrine therapy on
the basis of emerging data on the optimal duration of treatment, particularly adjuvant …

Background The optimal ways of using aromatase inhibitors or tamoxifen as endocrine
treatment for early breast cancer remains uncertain. Methods We undertook meta-analyses …

Background Extending the duration of adjuvant endocrine therapy reduces the risk of
recurrence in a subset of women with early-stage hormone receptor-positive (HR+) breast …

Summary Background The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial was
designed to compare the efficacy and safety of anastrozole (1 mg) with tamoxifen (20 mg) …

Purpose To develop evidence-based guidelines, based on a systematic review, for
endocrine therapy for postmenopausal women with hormone receptor–positive breast …

Purpose: Individualized selection of patients with early-stage hormone receptor–positive
(HR+) breast cancer for extended endocrine therapy (EET) is required to balance modest …